Fritextsökning
Innehållstyper
-
Satsar på tidig forskning
Tillsammans med tre universitet skapar Astrazeneca, GSK och Johnson and Johnson en fond för utveckling av prekliniska projekt.
-
Lytix calls in cash
Norwegian company Lytix Biopharma closes a USD 1.4 million funding round to finance new antimicrobial and oncology lead compounds.
-
New tools to fight bacteria
Better guidelines for doctors, detailed patient journals, and national monitoring systems are some of the tools needed to combat the increasing problem of antib...
-
Säkerhetsbrister på barnsjukhus
Knäckte lösenorden till skyddade dokument från prövningar
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten ...
-
Grape extract kills cancer cells
Grapes contain potentially beneficial chemicals that can destroy cancer cells, a new research proves.
-
Diamyd förlikar i licenstvist
Ger University of Florida en del av ersättningen de fick från affären med Ortho-McNeil-Janssen.
-
535 miljoner till regenerativ medicin
Knut och Alice Wallenbergs Stiftelse finansierar ett nytt forskningscentrum i Lund.
-
Sprint får ny vetenskaplig rådgivare
Cancerforskaren Ravi Amaravadi från USA ska hjälpa bolaget till klinisk fas.
-
Infidelity produces faster sperms
Until now, it has been difficult to prove that fast-swimming sperms have an advantage when it comes to fertilizing an egg.
-
A crash course in IP strategy
"Publish, publish, publish!" Sound familiar? So to meet the researcher's wishes, do you scribble a patent application with lipstick on a napkin and send it in? ...
-
Första Crispr-bolaget till börsen
Editas Medicine blir det första bolaget på börsen med fokus på det omtalade genmodifieringsverktyget Crispr/Cas9.
-
Nytt namn i Symphogens ledning
Adriann Sax har utsetts till affärschef på det danska företaget.
-
Schizophrenia and bipolar disorder are relatives
Schizophrenia and bipolar disorder have the same genetic causes, according to a study from Karolinska Institutet.
-
Medicult acquires embryo scanner
The Danish company Medicult signs an agreement with Novocellus to gain access to embryo selection technology.
-
Academy for a new turn at work
Are you qualified within life science, but unemployed? Here is your chance for a new career, in high demand.
-
Less scars with new product
A new Swedish product for post surgical scar formation enters clinical development.
-
Få överraskningar i rapporten
Pledpharmas kvartalsrapport bjöd inte på några stora nyheter men planerna på diskussioner med FDA och potentiella samarbetspartners ligger fast.
-
Swedish cancer therapy granted
Pledpharma, Linköping University and Ryhov County Hospital receive a research grant from the Research Council FORSS to conduct clinical studies in cancer patients.
-
Apoteket gets new vice CEO
The Swedish government company Apoteket has recently appointed a vice CEO.
-
Raysearch igång i Kina
Första patienten ombord i strålstudie.
-
Time to save for survival
The future is bright for the biotech industry. However, the companies need to cut costs immediately if they want to survive the rough economic times.
-
Norwegian cancer therapy leaves phase II
New clinical results from Algeta highlights the potential of Alpharadin to treat bone metastases in major cancer indications.
-
Smarta män tar sin medicin
Generell kognitiv förmåga har visat sig spela roll för hur väl män tar sin ordinerade medicin efter en hjärtinfarkt. Det visar en ny studie från Umeå och Uppsala universitet.